



Universiteit
Leiden
The Netherlands

Tamoxifen pharmacogenetics and pharmacokinetics in early breast cancer

Sanchez Spitman, A.B.

Citation

Sanchez Spitman, A. B. (2021, February 18). *Tamoxifen pharmacogenetics and pharmacokinetics in early breast cancer*. Retrieved from <https://hdl.handle.net/1887/3142390>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3142390>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <https://hdl.handle.net/1887/3142390> holds various files of this Leiden University dissertation.

Author: Sanchez Spitman, A.B.

Title: Tamoxifen pharmacogenetics and pharmacokinetics in early breast cancer

Issue Date: 2021-02-18

List of publications

Publications (in this thesis)

Sanchez-Spitman AB, Moes DJAR, Swen JJ, Dezentje VO, Lambrechts D, Neven P, Gelderblom H, Guchelaar HJ. Exposure-response analysis of endoxifen serum concentrations in early-breast cancer. *Cancer Chemother Pharmacol* 85, 1141–1152 (2020)

Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJAR, Gelderblom H, Guchelaar HJ. *CYP2C19* genotypes and tamoxifen therapy: effect on metabolism and early-breast cancer relapse. Submitted.

Sanchez-Spitman AB, Swen JJ, Dezentje VO, Moes DJAR, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. *Expert Rev Clin Pharmacol*. 2019 Jun;12(6):523-536.

Sanchez-Spitman AB, Dezentjé V, Swen J, Moes DJAR, Böhringer S, Batman E, van Druten E, Smorenburg C, van Bochove A, Zeillemaker A, Jongen L, Los M, Neven P, Gelderblom H, Guchelaar HJ. Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. *J Clin Oncol*. 2019 Mar 10;37(8):636-646.

Sanchez-Spitman AB, Dezentjé VO, Swen JJ, Moes DJAR, Gelderblom H, Guchelaar HJ. Genetic polymorphisms of 3'-untranslated region of *SULT1A1* and their impact on tamoxifen metabolism and efficacy. *Breast Cancer Res Treat*. 2018 Nov;172(2):401-411

Sanchez Spitman AB, Moes DJAR, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of *CYP3A4*22*, *CYP3A5*3*, and *CYP3A* combined genotypes on tamoxifen metabolism. *Eur J Clin Pharmacol*. 2017 Dec;73(12):1589-1598.

Sanchez-Spitman AB, Moes DJAR, Gelderblom H, Dezentjé VO, Swen JJ, Guchelaar HJ. The effect of rs5758550 on *CYP2D6*2* phenotype and formation of endoxifen in breast cancer patients using tamoxifen. *Pharmacogenomics*. 2017 Aug;18(12):1125-1132.

Other publications (not in this thesis)

Guchelaar HJ, Sanchez-Spitman AB, Dezentjé V, Böhringer S, Swen J, Neven P, Gelderblom H. Reply to C.L. Braal *et al*, H. Brauch *et al*, and M.P. Goetz *et al*. *J Clin Oncol*. 2019 Aug 1;37(22):1984-1985.

In preparation

Sanchez-Spitman AB, Böhringer S, Dezentjé VO, Gelderblom H, Swen JJ, Guchelaar HJ. A prospective genome-wide association study of endoxifen serum concentrations and adjuvant tamoxifen efficacy in early-breast cancer patients. *Manuscript in preparation*.

Acknowledgements

Pursuing a PhD has been a truly fascinating journey for me and it would not have been a reality without all the support and guidance I have received along this path.

First and foremost, I would like to thank my “promoters”, Prof. Henk-Jan Guchelaar and Prof. Hans Gelderblom, and “copromotor”, Dr. Vincent Dezentjé. You all have taught me that research is not about one person, but about being a team.

Henk-Jan, I would like to express my gratitude for all the excellent guidance, valuable support and exceptional suggestions to make this PhD journey so incredibly inspiring. Your sharp reasoning and ability to frame problems in unexpected manners are only matched by the joy you share in doing research. Hans, I would like to thank you for all your patience, continuous enthusiasm and optimism during these years. Your clinical eye and experience always were truly inspirational during this journey. Vincent, my appreciation for all your support and continuous energy, and specially for letting me to continue with the “CYPTAM study”.

My fellow researchers: Sofieke, Paul, Xiaoyan, Carin, Frank, Cathelijne, Maaïke, Michel, Anyue, Tom, Lisanne, Sylvia, Marieke, Emma and Sylvia. My gratitude for all your help.

This dissertation would not be without my dearest friends: Paty, Lola, Arja, Carla, Anouk, Tineke, Tania, Luci, Yoli, and many others. Thank you so much for your understanding, care and support. My friends from Delft: Xavi, Montse, Carlos, Marjolein, David, Adrian and Yaiza, thank you so much. Ana and Paco, thanks for the amusing time we always have. My special gratitude for Arun and Flavinha and the happiness you always give. Luiz Olavo and Luciana Bonino, thank for your caring. Minha família brasileira, Juvenal, Neusa, Vinicius, Paula, Benjamin, Benicio, Stella, Thales, Livia, Isadora e Rafaela muito obrigada por todo amor e carinho.

Mi familia: Mauricio, Carolina y Robert. Gracias por todo. Papa y mama, muchas gracias desde el fondo de mi corazón por todo el apoyo y amor incondicional que me habéis dado durante todos estos años.

Por último, pero lo más importante, Giovane, hace 4 años que empezamos esta aventura juntos, y solamente tengo palabras de gratitud, amor, y cariño por todo tu apoyo y enorme confianza en este largo y difícil proceso. Sin ti, no podría haber terminado este capítulo: muito obrigada, meu amor! No puedo esperar a continuar escribiendo los siguientes episodios de nuestra vida. Muchas gracias por ser un “nosotros”.

Curriculum vitae

Anabel Beatriz Sanchez-Spitman was born on the 1st of May 1982 in Benidorm (Spain). She is the daughter of the Spanish-Dutch couple Juan Sanchez and Lieke Spitman. After graduating from high school at the “Centro de Enseñanza Inmaculada Jesuitas”, Anabel started studying Pharmacy at the University of Valencia (Spain). She completed the 5 year program with a high remarkable mention. In 2007, she successfully passed the Spanish Pharmacy residency entrance exam and started her training as a hospital pharmacist at the General Hospital of Alicante (Spain). In the same year, she enrolled in the master program of Biomedicine and Biotechnology at the University of Alicante, where she graduated with honors (cum laude). In 2011, during the last year of her residency as hospital pharmacist, she worked for 3 months together with Dr. Barbara Maat and Prof. Dr. Toine Egberts at the Hospital Pharmacy Department in the University Medical Center of Utrecht (The Netherlands). From 2013 till 2016, she started studying the Bachelor of Medicine at the Leiden University, where she also followed and obtained the Honors Program of Leiden University. In 2015, she started as a part-time PhD candidate at the Leiden University Medical Center (LUMC), while combining it with the master of Medicine and the corresponding clinical clerkships. Her PhD project was supervised by Prof. Dr. Hans Gelderblom (Medical Oncology), Prof. Dr. Henk-Jan Guchelaar (Clinical Pharmacy and Toxicology) and Dr. Vincent Dezentjé (Netherlands Cancer Institute/Antoni van Leeuwenhoek). After ending her PhD, she will continue her clinical clerkships and will obtain her Medical Degree.

Anabel Sanchez-Spitman and her partner Giovane Moura live together in Delft (The Netherlands) with their daughter Elisa.